- AU$159.92m
- AU$150.65m
- AU$111.52m
- 79
- 48
- 99
- 87
Annual income statement for SomnoMed, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 62.7 | 72.6 | 83.6 | 91.7 | 112 |
| Cost of Revenue | |||||
| Gross Profit | 37.7 | 44.3 | 51.9 | 55.2 | 66.8 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 63.4 | 76.1 | 90.7 | 103 | 112 |
| Operating Profit | -0.734 | -3.5 | -7.05 | -11.3 | -0.764 |
| Net Income Before Taxes | -0.734 | -3.5 | -7.05 | -11.3 | -0.764 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.08 | -4.43 | -7.87 | -12.2 | -3.46 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -1.19 | -4.44 | -8 | -12.2 | -3.46 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.19 | -4.44 | -8 | -12.2 | -3.46 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.014 | -0.043 | -0.074 | -0.101 | -0.016 |